In May, the FDA approved GSK’s GSK RSV vaccine, Arexvy, forthe prevention of LRTD caused by RSV in older adults aged 60+ years. This was the first RSV vaccine for older adults to be approved ...
The EU on Friday authorised the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...
There's now another way to protect newborns from respiratory syncytial virus, or RSV, the leading cause of hospitalization ...
GSK has received approval from Japan’s MHLW for RSV vaccine Arexvy to prevent RSV disease in adults aged over 60 years ...
The FDA has approved the first long acting drug to protect infants and toddlers from the respiratory virus known as RSV. The antibody preventive therapy called, was approved Monday for injection ...
GSK plc has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its Arexvy (respiratory ...
For the first time, the U.S. has vaccines to fight a trio of viruses that cause fall and winter misery. But health officials ...
GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare ...
Pfizer PFE announced that the European Commission has approved its new vaccine, Abrysvo, for the prevention of respiratory syncytial virus (RSV) in infants through immunization of their pregnant ...
The EU on Friday authorised the sale of a vaccine to protect infants from respiratory syncytial virus (RSV), a disease that in worst cases can lead to pneumonia and bronchiolitis. The bloc-wide ...
The FDA approved Pfizer's maternal vaccine to protect newborns from RSV. - Courtesy Pfizer Still, the vaccine, given from 32 to 36 weeks of gestational age, does not provide long-term protection.
